Zuranolone is a neurosteroid that is inching its way toward FDA approval in depression. In some ways it’s similar to brexanolone (Zulresso) – the IV therapy approved in 2019 for postpartum depression – and in other ways it’s different.

CME: Take the CME Post-Test for this episode

Published On: 04/04/2022

Duration: 12 minutes, 20 seconds

Related Articles: “Brexanolone: A New Treatment for Postpartum Depression,” The Carlat Psychiatry Podcast, August 2019

“Brexanolone (Zulresso) for Postpartum Depression,” The Carlat Psychiatry Report, June 2019

“Brexanolone: A New Treatment for Postpartum Depression,” The Carlat Psychiatry Report, January 2019

Chris Aiken, MD, Kellie Newsome, PMHNP, and Margaret Chisolm, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.